Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy

What Echo Cannot Tell You — And When RHC Is Mandatory

Amyloid Series Urine Nephrology Now

Andrew Bland, MD, MBA, MS

← Amyloid Series Index

Executive Summary

Key Points

  • EF is a fraction (SV/EDV), not a measure of cardiac output — a "normal" EF can mask cardiogenic shock
  • An EF of 45–55% producing a CI <2.0 L/min/m² is the hemodynamic signature of infiltrative cardiomyopathy
  • Tissue Doppler (e’ velocity) and E/e’ ratio are more reliable than the E/A ratio for assessing diastolic function in amyloidosis
  • Global longitudinal strain with apical sparing ("bull’s-eye" pattern) has >80% sensitivity and specificity for cardiac amyloidosis
  • Echo cannot measure cardiac output, cannot differentiate ATTR from AL, and cannot assess hemodynamic severity — RHC is required when clinical severity exceeds echo findings
  • CI <2.2 L/min/m² defines low-output heart failure; CI <1.8 defines cardiogenic shock range

1. EF Is a Fraction, Not Output

EF = SV / EDV     where     CO = HR × SV     and     CI = CO / BSA

Ejection fraction measures what percentage of end-diastolic volume is ejected, not how much blood the heart delivers to the body. In a normal heart, the two correlate well. In an infiltrative cardiomyopathy, they dissociate dramatically because the stiff ventricle cannot fill adequately — EDV is reduced, making the ratio appear acceptable while absolute SV is critically low.

1.1 EF-CO Dissociation: Three Clinical Scenarios

ParameterNormal HeartDilated CM (EF 25%)Amyloid Heart (EF 55%)
EDV120 mL300 mL50 mL
SV72 mL75 mL28 mL
EF60%25%55%
HR70 bpm90 bpm85 bpm
CO5.0 L/min6.8 L/min2.4 L/min
CI (BSA 2.0)2.53.41.2
SVI36 mL/m²38 mL/m²14 mL/m²
ClinicalNormalCompensated HFCardiogenic shock

The Diagnostic Trap

The dilated cardiomyopathy with EF 25% has better cardiac output than the amyloid heart with EF 55%. A clinician who relies on EF alone will reassure themselves about the amyloid patient ("preserved EF, mild disease") while the patient is in hemodynamic extremis. SV and SVI, not EF, determine organ perfusion.

1.2 When EF and Hemodynamics Don’t Match

An EF of 45% that produces a CI of 1.75 L/min/m² represents a hemodynamic-EF mismatch. In dilated cardiomyopathy with EF 45%, cardiac output is typically far better maintained because the ventricle fills to a larger EDV. The "preserved EF with low output" pattern has a short differential:

2. Diastolic Parameters: The Real Story

Standard E/A ratio assessment frequently underestimates diastolic severity in amyloidosis due to pseudonormalization. Tissue Doppler provides load-independent assessment:

2.1 Key Parameters

ParameterWhat It MeasuresNormalAmyloid TypicalClinical Meaning
e’ septalIntrinsic myocardial relaxation velocity>7 cm/s3–5 cm/sDirect measure of myocardial stiffness; load-independent
E/e’Estimated filling pressure (correlates with PCWP)<1420–40+E/e’ >14 predicts PCWP >15 mmHg
MV E velocityEarly filling velocity (load-dependent)0.6–1.0 m/sOften elevatedReflects LA driving pressure
E/A ratioFilling pattern1–2VariableCan be "pseudonormalized" — misleading
Deceleration timeRate of E-wave decline160–240 ms<150 ms (restrictive)Short DT = high LA pressure, restrictive physiology

Clinical Pearl

An e’ velocity of 4 cm/s means the myocardium is relaxing at less than half the normal rate — it is functionally a brick. An E/e’ of 37 with e’ of 4 represents at minimum Grade II, likely transitional to Grade III diastolic dysfunction. If the echo report says "impaired relaxation" (Grade I) based solely on the E/A ratio while e’ is <5 and E/e’ is >20, the echocardiographer has underread the study. Always check tissue Doppler before accepting an E/A-based diastolic assessment.

2.2 The Pseudonormalization Trap

The E/A ratio can be "pseudonormalized" when elevated LA pressure pushes the E wave back up despite impaired relaxation. The pattern:

  1. Normal: E/A 1–2, e’ >7 — Normal filling
  2. Grade I (Impaired Relaxation): E/A <1, e’ <7 — True impaired relaxation
  3. Grade II (Pseudonormal): E/A 1–2, e’ <7 — Looks normal but e’ exposes the lie
  4. Grade III (Restrictive): E/A >2, DT <150 ms, e’ very low — Severe restriction

3. Global Longitudinal Strain and Apical Sparing

Global longitudinal strain (GLS) with an apical sparing pattern — the "cherry on top" or "bull’s-eye" pattern — is the most sensitive echocardiographic indicator of cardiac amyloidosis, with sensitivity and specificity both exceeding 80%.

In cardiac amyloidosis, amyloid fibrils deposit preferentially in the basal and mid-wall segments while the apex is relatively spared. This produces a characteristic pattern where basal GLS is severely reduced while apical GLS is preserved — visible as a red apex surrounded by blue/purple base and mid-segments on the bull’s-eye map.

Why EF Varies by Echo View in Amyloid

MethodEFExplanation
A4C (4-chamber)59%Weights apical function — which is preserved in amyloid
A2C (2-chamber)42%Weights basal function — which is impaired
Biplane (Simpson’s)52%Averages — masks the regional variation
Visual estimate31%Often underestimates when texture is abnormal
Fractional shortening31%Linear measure through basal segments

Clinical Pearl

A wide spread in EF across methods (31–59%) is itself abnormal and suggests regional variation in function — the hallmark of infiltrative disease with apical sparing. If you see a >15-point spread between A4C EF and A2C EF, request GLS with a bull’s-eye map.

4. What Echo Cannot Tell You

QuestionCan Echo Answer It?What Can
What is the cardiac output?No — estimated, not measuredRHC (thermodilution or Fick)
What is the true PCWP?Estimated via E/e’ (imprecise)RHC (direct measurement)
Is this ATTR or AL?No — both look identical on echoPYP scan + monoclonal screen; mass spectrometry amyloid typing
Is this restrictive or constrictive?Suggestive but not definitiveRHC (respirophasic ventricular interdependence)
Will diuresis cause hemodynamic collapse?No — cannot predict preload sensitivityRHC (Forrester classification; CI response to volume removal)
What is the RA pressure?Estimated via IVC diameter/collapseRHC (direct measurement)
Is there a pre-capillary component to PH?NoRHC (PVR, TPG, DPG)

5. When RHC Is Mandatory

Indications for RHC in Suspected or Confirmed Cardiac Amyloidosis

  • Clinical severity exceeds echo findings: Diuretic resistance, hypotension, AKI, vasopressor dependence with "preserved" EF
  • Volume management uncertainty: Defining safe operating filling pressures for the stiff ventricle
  • Restrictive vs. constrictive differentiation: When the hemodynamic pattern is ambiguous
  • Transplant evaluation: PVR assessment for cardiac or combined heart-liver transplant candidacy
  • Cardiogenic shock assessment: CI <2.2 suspected but echo cannot confirm

CI Thresholds and Their Clinical Meaning

CI (L/min/m²)Clinical StatusManagement Implication
2.5–4.0NormalStandard care
2.0–2.5Low-output heart failureCautious diuresis; monitor for AKI
1.8–2.0Pre-shockICU monitoring; vasopressor availability
<1.8Cardiogenic shockVasopressors, inotropes, or mechanical support; diuresis may be contraindicated without vasopressor support

Clinical Pearl

The hallmark teaching point: in any patient where diuresis causes hemodynamic collapse despite only mildly reduced EF, think infiltrative disease. The heart that "should" tolerate diuresis but does not is a heart that is stiffer than its EF suggests. The Frank-Starling curve is flat — output is already maximized at a fixed, small stroke volume, and any preload reduction drops output precipitously.

6. Additional Echo Findings in Amyloidosis

References

  1. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: AHA scientific statement. Circulation. 2020;142(1):e7-e22. PubMed
  2. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC review. J Am Coll Cardiol. 2019;73(22):2872-2891. PubMed
  3. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of LV diastolic function by echocardiography: ASE/EACVI update. J Am Soc Echocardiogr. 2016;29(4):277-314. PubMed
  4. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus on cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076-1126. PubMed
  5. Ladefoged B, Dybro A, Povlsen JA, et al. Diagnostic delay in ATTRwt cardiac amyloidosis. Int J Cardiol. 2020;304:138-143. PubMed
  6. Quarta CC, et al. AL amyloidosis for cardiologists. JACC CardioOncol. 2022;4(4):427-441. PubMed
  7. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using 2D speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-1448. PubMed
  8. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: AHA scientific statement. Circulation. 2019;139(4):e52-e154. PubMed

Amyloid Series Navigation

© Urine Nephrology Now | Amyloid Series
Andrew Bland, MD, MBA, MS